他汀类药物使用与年龄相关性黄斑变性发病率的荟萃分析
该系统检索截至2020年9月的文献,纳入21篇文章(1项随机对照试验和20项观察性研究,共1,460,989名参与者),评估他汀使用与年龄相关性黄斑变性(AMD)发病及进展风险的关系。结果显示他汀使用与任何AMD、早期AMD、晚期AMD的发病率均无显著差异,在已有AMD患者中与进展、脉络膜新生血管及地图样萎缩的发生率也无显著差异。
要点
- 他汀使用与任何AMD发病风险的合并风险比为1.05(95%CI 0.85-1.29,P=0.44),无显著差异。
- 他汀使用与早期及晚期AMD发病风险的合并风险比分别为0.99(95%CI 0.88-1.11,P=0.86)和1.15(95%CI 0.90-1.47,P=0.27)。
- 在已有AMD患者中,他汀使用与AMD进展、脉络膜新生血管及地图样萎缩风险的合并风险比分别为1.04(95%CI 0.70-1.53,P=0.85)、0.99(95%CI 0.66-1.48,P=0.95)和0.84(95%CI 0.58-1.22,P=0.36)。
核心结论
- 该荟萃分析发现,基于他汀使用情况,AMD的发病率或进展无显著差异。
研究设计与样本
- 系统检索MEDLINE、EMBASE、Cochrane CENTRAL及纳入研究的参考文献列表,检索时间从建库至2020年9月。
- 纳入标准为测量他汀使用与AMD发生或进展风险的研究。
- 共纳入21篇文章(1项随机对照试验和20项观察性研究),合计报告1,460,989名参与者。
主要发现
- 他汀使用与任何AMD发病风险的合并风险比为1.05(95%CI 0.85-1.29,P=0.44)。
- 他汀使用与早期AMD发病风险的合并风险比为0.99(95%CI 0.88-1.11,P=0.86)。
- 他汀使用与晚期AMD发病风险的合并风险比为1.15(95%CI 0.90-1.47,P=0.27)。
- 在已有AMD患者中,他汀使用与AMD进展风险的合并风险比为1.04(95%CI 0.70-1.53,P=0.85)。
- 在已有AMD患者中,他汀使用与脉络膜新生血管发生风险的合并风险比为0.99(95%CI 0.66-1.48,P=0.95),与地图样萎缩发生风险的合并风险比为0.84(95%CI 0.58-1.22,P=0.36)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Age-related macular degeneration (AMD) shares many of the same risk factors with atherosclerosis. There is a postulated role of lipid-lowering agents in preventing AMD. This meta-analysis investigates the possible role of statins in the prevention of AMD onset and progression. METHODS: MEDLINE, EMBASE, Cochrane CENTRAL, and the reference lists of included studies were systematically searched from inception to September 2020. Studies were included if they measured the risk of AMD development or progression with statin use. The primary outcomes assessed were AMD incidence and progression. Secondary outcomes were the incidence of early AMD, late AMD, choroidal neovascularization, and geographic atrophy. RESULTS: Twenty-one articles (1 randomized control trial and 20 observational studies) collectively reporting on 1,460,989 participants were included. The pooled risk ratios (95% confidence interval) for statin use on any, early, and late AMD incidence were 1.05 (0.85-1.29) (P = 0.44), 0.99 (0.88-1.11) (P = 0.86), and 1.15 (0.90-1.47) (P = 0.27), respectively. In patients with existing AMD, the respective risk ratios for statin use on incidence of AMD progression, choroidal neovascularization, and geographic atrophy were 1.04 (0.70-1.53) (P = 0.85), 0.99 (0.66-1.48) (P = 0.95), and 0.84 (0.58-1.22) (P = 0.36). CONCLUSION: This meta-analysis found that there was no significant difference in the incidence or progression of AMD based on statin use.
引用
- Eshtiaghi A, Popovic MM, Sothivannan A, et al. STATIN USE AND THE INCIDENCE OF AGE-RELATED MACULAR DEGENERATION: A Meta-Analysis. Retina. 2022. PMID: 34983903. doi:10.1097/IAE.0000000000003398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。